Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Lonza"


25 mentions found


Two years ago, when he was 68, that opportunity arose: McCaman cofounded Orion Therapeutics, a small company developing new ways for RNA medicine to reach specific areas of the human body. AdvertisementMcCaman, now 70, is the vice president and chief strategy officer at Orion Therapeutics. McCaman is passionate about staying engaged with his interests and said remote work has enabled him to extend his career. McCaman and Fischer launched Orion with Deidra Mountain, a University of Tennessee professor, and Jennifer Zachry, a graduate student. Are you a baby boomer who founded a small business?
Persons: , Michael McCaman, McCaman, It's, Davis, Intellia, Trey Fischer, Fischer, Jennifer Zachry, there's, John Deere Organizations: Service, Orion Therapeutics, Business, University of California San, University of California, Intellia Therapeutics, University of Tennessee, Orion, University of Tennessee Research Foundation, Launch Locations: Frederick , Maryland, Knoxville , Tennessee, University of California San Diego, California, Lonza, Maryland, Launch Tennessee
The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.
Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior
Barclays (BARC.L), a big UK lender, fell as much as 8% after signalling major cost cuts because of weakness on its home turf. Mark Denham, head of European equities at Carmignac, said high quality companies with high valuations tend to be very vulnerable if they miss earnings. According to Kasper Elmgreen, CIO at Nordea Asset Management, the fact that the economy is now starting to slow is one factor behind investors' harsh treatment of earnings disappointments. Amid the volatility, some investors see a buying opportunity in overly punished stocks. It is an example of a highly valued stock being extra punished for the environment," Denham said.
Persons: Morgan Stanley, Angelo Meda, Mark Denham, Denham, Kasper Elmgreen, Elmgreen, Fabio Di Giansante, Carmignac's Denham, Danilo Masoni, Alun John, Joice Alves, Amanda Cooper, Hugh Lawson Organizations: Sanofi, Barclays, Banor SIM, Siemens Energy, Volkswagen, Volvo, Asset Management, Euroland Equity, pharma, Thomson Locations: Milan, Swiss, London
A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. The market for semiconductor materials sold by the company's Electronics division, should "recover incrementally in 2024", Merck added. The company reaffirmed that sales would be broadly flat this year, at between 20.5 billion euros ($21.6 billion) and 21.9 billion euros, compared with 22.2 billion last year. The outlook for adjusted core earnings of 5.8 billion to 6.4 billion euros this year, down from 6.85 billion in 2022, was also confirmed. Higher interest rates have dampened investor appetite for risky biotech drug ventures, compounding a decline in coronavirus-related activities.
Persons: Ralph Orlowski, Belen Garijo, Morgan, Merck, JP Morgan, Garijo, Ludwig Burger, Rachel More, Elaine Hardcastle Organizations: Merck, REUTERS, company's Electronics, Lonza, Reuters, Thomson Locations: Darmstadt, Germany, FRANKFURT, coronavirus, Swiss
European shares open lower as Ericsson, miners weigh
  + stars: | 2023-10-17 | by ( ) www.reuters.com   time to read: +1 min
The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, July 7, 2023. REUTERS/Staff/File photo Acquire Licensing RightsOct 17 (Reuters) - European stocks opened lower on Tuesday, weighed down by a drop in Ericsson shares following downbeat quarterly results and weakness in the mining sector as investors monitored risks from an escalation in the Middle East conflict. The pan-European STOXX 600 index (.STOXX) was down 0.1% by 0705 GMT, with miners (.SXPP) among the top decliners, down 0.6% as copper prices slipped. Shares of Ericsson (ERICb.ST) dropped 7.3% after the Swedish network equipment provider flagged that ongoing uncertainty impacting its mobile networks business will persist into 2024, after reporting a fall in third-quarter revenue. Shares of Lonza (LONN.S) dropped 11.5% after the contract drugmaker cut its 2024 margin target again following the abrupt departure of its CEO last month.
Persons: Amruta Khandekar, Sherry Jacob, Phillips Organizations: REUTERS, Staff, Ericsson, Royce, Thomson Locations: Frankfurt, Germany, Swedish, British
Weight-loss drugs fuel boom for firms that fill syringes
  + stars: | 2023-10-09 | by ( Maggie Fick | ) www.reuters.com   time to read: +6 min
[1/5] Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Eli Lilly's (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year. The U.S. Inflation Reduction Act is also boosting development of biologic drugs, some of which are injected. Injectables are increasingly used in elderly care settings, and some new Alzheimer's and generic arthritis drugs are administered by injection. One healthcare investor said CDMOs' ability to boost capacity will determine how fast the obesity drug market grows.
Persons: Wegovy, it's, Savant, Morgan Stanley, Eli Lilly's, Mounjaro, Chris Chen, Cornell Stamoran, Fujifilm Diosynth, Germany's Vetter, Lilly, Marc Casper, CDMOs, Luke Sergott, Catalent, Catalent's Stamoran, Maggie Fick, Patrick Wingrove, Josephine Mason, Catherine Evans Organizations: REUTERS Acquire, Pfizer, HK, Fujifilm, Fujifilm Corp, Novo, Reuters, Research, Insight Partners, Barclays, Thomson Locations: Brussels, Belgium, Handout, United States, WuXi, Europe, GLP, Anagni, Italy, Bloomington , Indiana, U.S, New York
UK disinflationary shock sharpens Bailey’s dilemma
  + stars: | 2023-09-20 | by ( ) www.reuters.com   time to read: +2 min
Governor of the Bank of England Andrew Bailey speaks as he attends a press conference for the Monetary Policy Report August 2023, at the Bank of England in London, Britain, August 3, 2023. Alastair Grant/Pool via REUTERS Acquire Licensing RightsLONDON, Sept 20 (Reuters Breakingviews) - Bank of England Governor Andrew Bailey finally got some good news on Wednesday. UK annual inflation fell to 6.7% in August, from 6.8% in July, confounding market expectations of a rise to 7%. Domestic disinflationary forces offset a nearly 30% rise in oil prices to bring headline inflation to the lowest level since February 2022. Higher petrol prices did add around 0.3 percentage points to the consumer price index, according to Capital Economics.
Persons: Bank of England Andrew Bailey, Alastair Grant, Andrew Bailey, disinflation, Francesco Guerrera, Bernie Sanders’s, Neil Unmack, Streisand Neto Organizations: Bank of England, Monetary, REUTERS Acquire, Reuters, Capital Economics, CPI, Thomson Locations: London, Britain
Bernie Sanders’s push for four-day weeks has merit
  + stars: | 2023-09-19 | by ( ) www.reuters.com   time to read: +2 min
Senator Bernie Sanders speaks to the crowd as United Auto Workers President Shawn Fain and UAW Region 1 Director LaShawn English listen during a rally in support of striking UAW members in Detroit, Michigan, U.S., September 15, 2023. The United Auto Workers on Friday began strikes at Detroit carmakers Ford Motor (F.N), General Motors (GM.N) and Stellantis (STLAM.MI). Sanders voiced enthusiasm for their biggest demand: moving to a four-day workweek while maintaining five-day pay. UAW members pushed for this policy in the middle of the last century during a prior wave of automation. With artificial intelligence poised to reshape white-collar jobs, more workers might come to see things Sanders’s way.
Persons: Bernie Sanders, Shawn Fain, Rebecca Cook, Sanders, Jim Farley, Jonathan Guilford, Lauren Silva Laughlin, Sharon Lam Organizations: United Auto Workers, UAW, REUTERS, Reuters, Friday, Detroit, Ford, General Motors, X, Thomson Locations: Detroit , Michigan, U.S
Retail park bounce adds nail to high street coffin
  + stars: | 2023-09-19 | by ( ) www.reuters.com   time to read: +2 min
LONDON, Sept 19 (Reuters Breakingviews) - Retail parks are a beacon of hope in a gloomy UK property market. Since their 2015 peak, average retail rents have come down by a third, analysts estimate. Retail parks are also good for e-commerce as they allow customers to drop off and pick up orders. That’s not the case on the high street, where business rates and high rents have driven tenants out. Today’s 2.5% rise in its shares suggests investors need more than growing retail parks to be convinced of its prospects.
Persons: That’s, Aimee Donnellan, Francesco Guerrera, Oliver Taslic Organizations: Reuters, Sports, Land, Centre for Retail Research, X, Thomson
Planet Fitness races against rate hikes
  + stars: | 2023-09-18 | by ( ) www.reuters.com   time to read: +2 min
View of the Planet Fitness logo at the their location in Clifton, New Jersey, U.S., January 6, 2023. REUTERS/Jennifer Saba Acquire Licensing RightsNEW YORK, Sept 18 (Reuters Breakingviews) - Planet Fitness (PLNT.N) is struggling to adapt to a high-interest-rate diet. Under Rondeau, Planet Fitness benefited from a post-pandemic exercise rebound, notching annual sales growth of over 40% in the last two years as location count expanded by 13%. Its stock is up 32% this year, while Planet Fitness’s is down by roughly the same amount. Life Time boss Bahram Akradi said his old approach of keeping prices low was a “mistake.” Planet Fitness can fix the same error.
Persons: Jennifer Saba, Chris Rondeau, Rondeau, Fitness’s, Bahram Akradi, Anita Ramaswamy, Jonathan Guilford, Sharon Lam, Aditya Sriwatsav Organizations: REUTERS, Reuters, Planet, X, Thomson Locations: Clifton , New Jersey, U.S
S4 misery offers reality check on tech exuberance
  + stars: | 2023-09-18 | by ( ) www.reuters.com   time to read: +2 min
LONDON, Sept 18 (Reuters Breakingviews) - Is the technology sector bouncing back? The tech-heavy Nasdaq Composite Index (.IXIC) is up 31% this year, and chip designer Arm enjoyed a 25% first-day pop on its listing. S4 on Monday downgraded its 2023 like-for-like net revenue growth forecast to “down on last year”. The news still sent S4 shares down 25% on Monday morning. Any recovery will require Sorrell to show he can keep winning business in an era of tech uncertainty.
Persons: Martin Sorrell, That’s, Publicis, Sorrell, Oliver Taslic, Neil Unmack, Streisand Neto Organizations: Reuters, Nasdaq, S4, Nvidia, Meta, X, Thomson
The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, dropped 5.3% shortly after the 0700 GMT market open, trading near an eight-month low. A former Roche executive who joined Lonza in 2020, Ruffieux oversaw the company's role in producing COVID-19 vaccines for Moderna (MRNA.O) during the pandemic. "Today’s announcement increases our conviction that the new mid-term targets will not include an acceleration in growth," they said. Lonza did not provide a reason for Ruffieux's departure.
Persons: Arnd, Pierre, Alain Ruffieux, Lonza, Albert Baehny, Ruffieux, Morgan, Spokespeople, Merck KGaA, Noele, Ludwig Burger, Rachel More, David Goodman, Emelia Organizations: REUTERS, Monday, Ruffieux, Roche, Lonza, Moderna, Merck, Noele Illien, Thomson Locations: Basel, Switzerland, Swiss, Lonza, Zurich, Frankfurt
Lonza’s CEO churn adds to company’s ailments
  + stars: | 2023-09-18 | by ( ) www.reuters.com   time to read: +2 min
REUTERS/Denis Balibouse Acquire Licensing RightsLONDON, Sept 18 (Reuters Breakingviews) - Lonza’s (LONN.S) new broom will face even more challenges than its old one. Since he was appointed CEO in 2020, the Swiss group has increased capital expenditure as a percentage of revenue from 20% to 30% last year. Even before Monday’s fall, the stock was trading at 32 times its forward earnings, around the same level as before its pandemic surge. The disruption of another CEO exit, without a clear explanation, means that the hoped-for growth will take even longer to arrive. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Persons: Denis Balibouse, Pierre, Alain Ruffieux, Albert Baehny, Aimee Donnellan, Neil Unmack, Streisand Neto Organizations: REUTERS, Reuters, Swiss, X, Thomson Locations: Lonza, Visp, Switzerland, Swiss
This segment also handles the formulation, development and manufacturing for parenteral dose forms, including vials and prefilled syringes. Activist Commentary: Elliott is a very successful and astute activist investor, particularly in the technology sector. While as an activist Elliott will do whatever it feels is necessary to enhance shareholder value, in the past the firm has made significant use of the strategy of offering to acquire its portfolio companies as the best catalyst to enhance shareholder value. Like Catalent, Syneos is an outsourced pharma solutions company: It outsources R&D for pharmaceutical companies, whereas Catalent outsources manufacturing. If this does turn from a strategic review to an operational review, there is no guarantee that he keeps his job.
Persons: Catalent, there's, Elliott, Steven Barg, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Johnson, Barg, Ryan, John Greisch, There's, Danaher, Alessandro Maselli, Ken Squire Organizations: Oral Technologies, Clinical, Pfizer, Rom Holdings, Bloomberg, Merck, Citrix Systems, Nielsen Holdings, Square, Veritas Capital, Syneos Health, 13D Locations: COOs, North America
2seventy bio to lay off 40% of workforce; CEO to step down
  + stars: | 2023-09-12 | by ( ) www.reuters.com   time to read: +2 min
Nick Leschly, CEO of bluebird, speaks at the opening of Lonza Houston, the world’s largest dedicated cell and gene therapy facility, in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer Acquire Licensing RightsSept 12 (Reuters) - 2seventy bio (TSVT.O) said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in premarket trade. The company added that CEO Nick Leschly will step down and transition to the role of chairman. Leschly was earlier the CEO of bluebird bio (BLUE.O) for 11 years, but changed role after the gene therapy maker's oncology portfolio was spun off from it as 2seventy. The company will now focus on another type of multiple myeloma patients, for which it expects approval from the U.S. Food and Drug Administration in mid-December.
Persons: Nick Leschly, Lonza, Daniel Kramer, Leschly, 2seventy, Abecma, Johnson, Bristol Myers, William Baird, Pratik Jain, Shounak Dasgupta, Maju Samuel Organizations: bluebird, REUTERS, Johnson, Legend Biotech, Bristol, Bristol Myers Squibb, U.S . Food, Drug Administration, Thomson Locations: Lonza Houston, Houston , Texas, U.S, Abecma, Bengaluru
Portfolio manager Elias Erickson focuses on finding stocks that can withstand market fluctuations. With the bull market still flourishing, current stock market conditions are a far cry from where they began the year. Coming off last October's market lows, a series of macroeconomic factors have given equities plenty of whiplash this year. "We're trying to buy businesses that will be adaptable to a variety of different macroeconomic environments," Erickson explained to Insider in an interview. Constellation Software, a Canadian-based acquirer of vertical market software, also makes up one of Erickson's largest positions.
Persons: Elias Erickson, Roger Altman, Paul Krugman, Elias Erickson isn't, Erickson, That's, Hermès, they've, Sartorius Organizations: SAP, Constellation Software, Constellation, Mastercard Locations: Canadian, Lonza
The firm is known for growth investing, but she says she's picking defensive, stable winners. Mileva told Insider about some of the industries and stocks she likes the most today. How is a company that's known for board games and fantasy figurines anything like a company that owns world famous luxury brands with products like high fashion accessories, champagne, and yachts? That's the view of Milena Mileva, the manager of Baillie Gifford's $564 million Developed EAFE All Cap fund, and an expert on international stocks. These are the ones that historically have been the most successful examples," she told Insider in a recent interview.
Goldman Sachs has named eight global stocks of companies that will become profitable this year and beat the broader market. In a new research report, the investment bank found that companies that transition from unprofitable to profitable during a market recovery typically outperform the broader market. Goldman Sachs also said stocks of European companies undergoing this transition are already showing signs of outperformance against the Stoxx 600 by 6%. Pan-European classifieds operator Adevinta and Swiss solar power engineering firm Meyer Burger are also expected to turn profitable this year. However, Goldman cautioned that the bank isn't certain the market has reached its bottom, and the trend applies only in a market recovery scenario.
[1/2] A logo is pictured on the Ibex building of Lonza, where the Moderna mRNA coronavirus disease (COVID-19) vaccine will be produced, in Visp, Switzerland, September 29, 2020. REUTERS/Denis Balibouse/File PhotoJan 25 (Reuters) - Lonza (LONN.S) on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The Basel-based company, however, reiterated a target of 33%-35% for 2024 marginsand announced a 17% rise in its annual dividend. The Swiss group forecast sales growth in the "high single-digit" adjusted for currency swings, a slow-down from the 15.1% rise it saw last year.
European shares slip as investors weigh earnings reports
  + stars: | 2023-01-25 | by ( ) www.reuters.com   time to read: +1 min
Jan 25 (Reuters) - European stocks inched lower on Wednesday as investors assessed a slew of earnings reports including chip equipment maker ASML's, while fears of more interest rate hikes kept investors on edge. The pan-European STOXX 600 (.STOXX) fell 0.2% by 0816 GMT, with technology (.SX8P) and financials declining the most. Shares of ASML Holding NV (ASML.AS) lost 2% and were among the top drags on the STOXX 600, despite forecasting sales growth of more than 25% for 2023. Lonza Group AG (LONN.S) fell 2.8%, even as the Swiss drug contract manufacturer reaffirmed its longer-term growth prospects. Investors will monitor Germany's 2023 annual economic report in Berlin due at 1315 GMT amid easing fears of a recession in the euro zone's largest economy.
REUTERS/Evelyn HocksteinHONG KONG, Sept 14 (Reuters Breakingviews) - China biotech’s American honeymoon is ending. Key to his initiative is ensuring that “biotechnologies invented in the United States of America are made in the United States of America”. With more bad news set to trickle out of Washington, Chinese biotech companies have a bitter pill to swallow. The order "directs the federal government to ensure biotechnologies invented in the United States of America are made in the United States of America," Biden said. Hong Kong shares of WuXi Biologics, a Chinese contract drug manufacturer, closed down 20% on Sept. 13 to HK$53.40.
Compania farmaceutică anglo-suedeză AstraZeneca a anunţat marţi că, în urma unui studiu clinic, tratamentul său bazat pe anticorpi monoclonali, AZD7442, nu şi-a atins obiectivul principal de prevenire a formelor simptomatice de COVID-19 în cazul persoanelor expuse recent la noul coronavirus, informează Reuters, citează Agerpres. AZD7442 a redus riscul de a dezvolta o formă simptomatică de COVID-19 cu 33% în comparaţie cu grupul placebo, ceea ce nu este semnificativ din punct de vedere statistic, a mai precizat compania. AstraZeneca analizează tratamentul şi într-un studiu cu pacienţi pre-expuşi, precum şi pentru prevenirea unor forme mai grave ale bolii. Tratamentul cu anticorpi monoclonali face parte dintr-o clasă de medicamente care imită anticorpii naturali pe care organismul îi produce pentru a lupta cu o infecţie. AstraZeneca a anunţat în martie semnarea unui contract cu guvernul american pentru furnizarea a jumătate de milion de doze de AZD7442.
Persons: Reuters, AZD7442, Eli Lilly, Celltrion, Vir, AstraZeneca Organizations: Regeneron Pharmaceuticals, Vir Biotechnology Inc Locations: Statele Unite, Portsmouth, New Hampshire, Statelor Unite, SUA
Compania farmaceutică anglo-suedeză AstraZeneca a anunţat marţi că, în urma unui studiu clinic, tratamentul său bazat pe anticorpi monoclonali, AZD7442, nu şi-a atins obiectivul principal de prevenire a formelor simptomatice de COVID-19 în cazul persoanelor expuse recent la noul coronavirus, informează Reuters, citează Agerpres. AZD7442 a redus riscul de a dezvolta o formă simptomatică de COVID-19 cu 33% în comparaţie cu grupul placebo, ceea ce nu este semnificativ din punct de vedere statistic, a mai precizat compania. AstraZeneca analizează tratamentul şi într-un studiu cu pacienţi pre-expuşi, precum şi pentru prevenirea unor forme mai grave ale bolii. Tratamentul cu anticorpi monoclonali face parte dintr-o clasă de medicamente care imită anticorpii naturali pe care organismul îi produce pentru a lupta cu o infecţie. AstraZeneca a anunţat în martie semnarea unui contract cu guvernul american pentru furnizarea a jumătate de milion de doze de AZD7442.
Persons: Reuters, AZD7442, Eli Lilly, Celltrion, Vir, AstraZeneca Organizations: Regeneron Pharmaceuticals, Vir Biotechnology Inc Locations: Statele Unite, Portsmouth, New Hampshire, Statelor Unite, SUA
Sursa foto: Getty ImagesStudiu: Tratamentul AstraZeneca pe bază de anticorpi nu este eficient în prevenirea COVID-19Un studiu clinic privind o terapie cu anticorpi împotriva COVID-19 dezvoltat de compania farmaceutică AstraZeneca a arătat că tratamentul nu este eficient, a anunțat compania. AZD7442 - o combinație de doi anticorpi monoclonali diferiți - nu a dovedit o reducere semnificativă a riscului de COVID-19 simptomatic după expunerea la virus. Potrivit companiei, la studiu au participat adulţi nevaccinaţi cu vârste de peste 18 ani, care au confirmat expunerea la o persoană infectată cu coronavirus în ultimele opt zile. AZD7442 a redus riscul de a dezvolta o formă simptomatică de COVID-19 cu 33% în comparaţie cu grupul placebo, ceea ce nu este semnificativ din punct de vedere statistic, a mai precizat compania. AstraZeneca a semnat în octombrie un acord cu producătorul contractant Lonza pentru a produce medicamentul pe bază de anticorpi în Portsmouth, New Hampshire, începând cu prima jumătate a anului 2021.
Persons: AZD7442, AstraZeneca Locations: Portsmouth, New Hampshire
De asemenea, investiţiile făcute vor permite partenerului Lonza Group, care este responsabil de livrările pentru pieţele externe, să îşi dubleze producţia de vaccin la uzina sa din Elveţia. Cu toate acestea, Moderna a subliniat că numărul exact de doze de vaccin pe care le va produce anul viitor va depinde de mai mulţi factori, precum mixul dintre actualele vaccinuri, care utilizează o doză mai mare de substanţă activă, şi vaccinurile care acum sunt în faza de testare, care ar putea utiliza o doză mai mică de substanţă activă. "Aproape ne vom dubla capacităţile în anul următor", a declarat directorul general de la Moderna, Stephane Bancel.Acesta a adăugat că grupul american va cheltui miliarde de dolari pentru extinderea capacităţilor, dar nu a oferit o cifră precisă. Cu toate acesta, Bancel a spus că în ultimele săptămâni a fost asaltat de telefoane din partea altor ţări care vor să comande mai multe doze. "Telefonul meu a sunat în continuu luna trecută", a spus Stephane Bancel.Anterior, Moderna prognoza că în 2022 va produce 1,4 miliarde de doze din actualul său vaccin sau până la 2,8 miliarde doze dacă va face tranziţia la producţia noului tip de vaccin care ar putea utiliza o doză mai mică de substanţă activă.Tot joi, Moderna şi-a îmbunătăţit şi estimările privind nivelul minim al producţiei preconizate pentru acest an, de la 700 până la 800 milioane doze de vaccin.
Persons: Stephane Bancel.Acesta, Bancel, Stephane Organizations: american, Moderna Locations: american Moderna, SUA, Europa, Norwood, Massachusetts, Elveţia, Spania, american New Jersey.Ingredientele, Moderna, Europei, Canadei, Japoniei, Coreei de Sud
Total: 25